Enanta Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Fiscal first quarter ended December 31, 2023; compared with the three months ended December 31, 2022. Amounts below are in U.S. dollars.
Business context
Enanta is a biotechnology company developing small-molecule medicines, primarily for virology and immunology. Its principal revenue source is royalties from AbbVie’s HCV treatment MAVYRET/MAVIRET. The company is advancing RSV candidates, while its COVID-19, HBV, and CSU programs are at differing development stages.
Financial performance and liquidity
| Metric | Q1 FY2024 | Q1 FY2023 |
|---|---|---|
| Revenue | $18.0 million | $23.6 million |
| Research and development expense | $36.4 million | $40.9 million |
| General and administrative expense | $16.5 million | $12.7 million |
| Loss from operations | $34.9 million | $30.0 million |
| Net loss | $33.4 million | $29.0 million |
| Net loss per share, basic and diluted | $1.58 | $1.39 |
| Net cash used in operating activities | $25.0 million | $35.6 million |
- Revenue fell $5.6 million, or about 24%, mainly because of lower AbbVie HCV sales and the absence of $1.0 million of prior-year license revenue.
- R&D expense decreased $4.5 million as COVID-19 and HBV spending declined; RSV and new immunology spending increased. G&A rose $3.8 million, reflecting higher stock-based compensation and legal costs.
- Interest expense of $3.4 million arose from the OMERS royalty-sale arrangement; higher interest and investment income partly offset it.
- At December 31, 2023, cash, cash equivalents, and short-term marketable securities totaled $337.2 million. Total assets were $428.5 million and stockholders’ equity was $191.9 million.
- The royalty-sale liability was $188.1 million, including $36.5 million current and $151.6 million long-term. This is a financing-related obligation rather than conventional borrowings.
- Cash, cash equivalents, and restricted cash decreased $45.5 million during the quarter. Investing cash flow was negative $13.1 million, largely reflecting purchases and maturities of marketable securities; financing cash use included $7.2 million paid to OMERS.
Material changes, outlook, and risks
- Under the April 2023 OMERS agreement, Enanta received $200 million in exchange for 54.5% of future MAVYRET/MAVIRET royalties after June 30, 2023 through June 30, 2032, subject to a payment cap of 1.42 times the purchase price. Enanta continues to report 100% of royalties as revenue but retains only 45.5% of the related cash royalties during the agreement term.
- Management said available resources, together with retained future HCV royalties, are expected to fund operations and capital expenditures through fiscal 2027. The filing also cautions that actual results and funding needs may differ from this forecast.
- Management expects external R&D spending generally to decrease over the next 12 months, in part because Enanta will not advance EDP-235 into Phase 3 on its own. Further development would depend on collaboration opportunities.
- Enanta anticipated RSVPEDs data and EDP-323 Phase 2 challenge-study topline data in the third quarter of calendar 2024, and aimed to select a KIT inhibitor lead candidate in late 2024. These are forward-looking expectations, not reported outcomes.
- Key risks include declining or variable AbbVie HCV sales, competition across HCV and development programs, clinical-trial and regulatory uncertainty, and the possibility that additional financing or partnerships may be needed.
- Enanta is suing Pfizer in a patent-infringement case concerning Paxlovid and is seeking compensation. The company records legal costs as incurred; the filing does not provide a clear value for any potential recovery.
- After quarter-end, Enanta disclosed a February 8, 2024 employment agreement related to the Chief Legal Officer’s planned retirement. It provides for continued part-time service and accelerates vesting of certain equity awards.
Important facts for investors to verify
- Subsequent AbbVie sales and royalty trends, and the resulting effect of the annual royalty-tier reset and OMERS cash-sharing arrangement.
- Whether cash use, clinical spending, and the projected runway through fiscal 2027 remain consistent with management’s assumptions.
- Clinical progress and reported results for zelicapavir and EDP-323, plus any partnership for EDP-235.
- Developments in the Pfizer patent litigation, including costs and any material changes in the case.
- The status and terms of any future financing, licensing, or collaboration arrangements.